Oric Pharmaceuticals, Inc. recently disclosed important stock transactions involving Richard A. Heyman, a director of the company. The transactions, reported in a filing dated October 2, 2026, reveal both acquisitions and disposals of shares, which are significant for the company and the broader pharmaceutical industry.
Background
Oric Pharmaceuticals, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates within the Nasdaq exchange under the ticker symbol ORIC. The company is focused on developing innovative therapies for cancer treatment. Recent filings include a Form 8-K on October 23, 2026, and multiple Form 4 filings, indicating ongoing activity and transparency in its operations.
What the Filing Says
The filing indicates that on October 1, 2026, Heyman engaged in several transactions involving Oric's common stock. Specifically, he acquired 3,500 shares at a price of $1.60 each and disposed of 6,700 shares at prices ranging from $12.57 to $13.39. Following these transactions, Heyman holds a total of 20,472 shares directly and has investment power over additional shares held by RAHD Capital, LLC.
“The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.”
Impact
These transactions may affect investor sentiment towards Oric Pharmaceuticals, as they reflect strategic decisions by a key company director. The pharmaceutical preparations industry is closely monitored by investors, and such disclosures can influence market perceptions and stock performance.
What's Next
The filing does not say what happens next.